GlassScriptPhysician profile
Vincent John Pompili
NPI 1720008360
$10,842.24
in general payments reported to CMS, 2019-2025
24 companies · $332 in 2025
The $332 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $5,319 · 2021: $2,338 · 2022: $251 · 2023: $1,067 · 2024: $1,175 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,937 · Travel and Lodging: $638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,936.55 |
| Travel and Lodging | $638.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $8,598.67 | 2019-2025 | Avvigo Guidance System, Watchman Access System, Ingevity+ |
| Medtronic, INC. | $753.98 | 2023-2025 | Micra, Corevalve Evolut R |
| Abbott Laboratories | $299.34 | 2021-2025 | Aveir, Cardiomems, Xience Skypoint |
| Abiomed | $261.63 | 2021-2025 | Impella |
| Edwards Lifesciences Corporation | $233.69 | 2024-2025 | Sapien 3 Ultra Resilia |
| Pfizer INC. | $133.03 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $114.38 | 2022-2025 | |
| Amgen INC. | $75.34 | 2022-2025 | Repatha, Repatha |
| Stereotaxis INC | $42.57 | 2020 | |
| Acist Medical Systems, INC. | $41.89 | 2024 | |
| Cvrx, INC. | $32.12 | 2023-2024 | Barostim Neo System |
| Kiniksa Pharmaceuticals International, Plc | $30.36 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $29.99 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $26.06 | 2022 | |
| Philips North America LLC | $21.09 | 2024 | (Bq9) Coronary Ivus |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.11 | 2022 | |
| Biotronik INC. | $19.90 | 2025 | Orsiro Mission |
| Scpharmaceuticals INC. | $17.62 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.67 | 2025 | |
| Elutia, INC. | $15.47 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $15.12 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.10 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.85 | 2024 | Farxiga |
| Novo Nordisk INC | $14.26 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Pompili listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.